463 related articles for article (PubMed ID: 23993415)
1. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.
Wen S; Niu Y; Lee SO; Chang C
Cancer Treat Rev; 2014 Feb; 40(1):31-40. PubMed ID: 23993415
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor enhances entosis, a non-apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells.
Wen S; Shang Z; Zhu S; Chang C; Niu Y
Prostate; 2013 Sep; 73(12):1306-15. PubMed ID: 23775364
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
4. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
[TBL] [Abstract][Full Text] [Related]
5. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
6. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
7. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.
Lee SO; Ma Z; Yeh CR; Luo J; Lin TH; Lai KP; Yamashita S; Liang L; Tian J; Li L; Jiang Q; Huang CK; Niu Y; Yeh S; Chang C
J Mol Cell Biol; 2013 Feb; 5(1):14-26. PubMed ID: 22831834
[TBL] [Abstract][Full Text] [Related]
8. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Dependence.
Chaturvedi AP; Dehm SM
Adv Exp Med Biol; 2019; 1210():333-350. PubMed ID: 31900916
[TBL] [Abstract][Full Text] [Related]
11. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
[TBL] [Abstract][Full Text] [Related]
12. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
13. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
14. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
15. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.
Derderian S; Benidir T; Scarlata E; Altaylouni T; Hamel L; Zouanat FZ; Brimo F; Aprikian A; Chevalier S
J Pathol Clin Res; 2023 Jul; 9(4):285-301. PubMed ID: 37073437
[TBL] [Abstract][Full Text] [Related]
16. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
17. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
Hu S; Li L; Yeh S; Cui Y; Li X; Chang HC; Jin J; Chang C
Mol Oncol; 2015 Jan; 9(1):44-57. PubMed ID: 25135278
[TBL] [Abstract][Full Text] [Related]
18. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
20. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.
Nyquist MD; Dehm SM
Horm Cancer; 2013 Apr; 4(2):61-9. PubMed ID: 23307762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]